PDCD1LG2 and neoplasm: The immune phenotypes of the patients’ tumor milieu demonstrated overexpression of multiple checkpoint blockade markers including PD-L1 (6.9%), PD-L2 (10.9%), CTLA4 (3%), LAG-3 (8.9%), TIM-3 (9.9%) and VISTA (15.8%).